Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

被引：280

作者：

Hogarth, P. Mark ^{[1
,2
,3
]}

Pietersz, Geoffrey A. ^{[2
,3
,4
]}

机构：

[1] Burnet Inst, Ctr Immunol, Inflammat Canc & Infect Lab, Melbourne, Vic 3004, Australia

[2] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia

[3] Monash Univ, Dept Immunol, Clayton, Vic 3168, Australia

[4] Burnet Inst, Ctr Immunol, Bioorgan & Med Chem Lab, Melbourne, Vic 3004, Australia

来源：

NATURE REVIEWS DRUG DISCOVERY | 2012年 / 11卷 / 04期

基金：

英国医学研究理事会;

关键词：

COLLAGEN-INDUCED ARTHRITIS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CHRONIC LYMPHOCYTIC-LEUKEMIA; DEPENDENT CELLULAR CYTOTOXICITY; IMMUNE THROMBOCYTOPENIC PURPURA; ANTI-CD20; MONOCLONAL-ANTIBODY; ANTIGEN-INDUCED ARTHRITIS; GENOME-WIDE ASSOCIATION; AFFINITY IGE RECEPTOR; HUMAN MAST-CELLS;

D O I：

10.1038/nrd2909

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The direct or indirect targeting of antibody Fc receptors (FcRs) presents unique opportunities and interesting challenges for the treatment of inflammatory diseases, cancer and infection. Biological responses induced via the Fc portions of antibodies are powerful, complex and unusual, and comprise both activating and inhibitory effects. These properties can be exploited in the engineering of therapeutic monoclonal antibodies to improve their activity in vivo. FcRs have also emerged as key participants in the pathogenesis of several important autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. Therapeutic approaches based on antagonizing FcR function with small molecules or biological drugs such as monoclonal antibodies and recombinant soluble FcR ectodomains have gained momentum. This Review addresses various strategies to manipulate FcR function to overcome immune complex-mediated inflammatory diseases, and considers approaches to improve antibody-based anticancer therapies.

引用

收藏

页码：311 / U87

页数：21

相关论文

共 170 条

[11] Fc-γRI-deficient mice show multiple alterations to inflammatory and immune responses [J].

Barnes, N ;

Gavin, AL ;

Tan, PS ;

Mottram, P ;

Koentgen, F ;

Hogarth, PM .

IMMUNITY, 2002, 16 (03) :379-389

[12] Differential contribution of three activating IgG Fc receptors (FcγRI, FcyRIII, and FcγRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice [J].

Baudino, Lucie ;

Nimmerjahn, Falk ;

da Silveira, Samareh Azeredo ;

Martinez-Soria, Eduardo ;

Saito, Takashi ;

Carroll, Michael ;

Ravetch, Jeffrey V. ;

Verbeek, J. Sjef ;

Izui, Shozo .

JOURNAL OF IMMUNOLOGY, 2008, 180 (03) :1948-1953

[13] Intravenous immunoglobulin in autoimmune disorders: An insight into the immunoregulatory mechanisms [J].

Bayry, J ;

Dasgupta, S ;

Misra, N ;

Ephrem, A ;

Van Huyen, JPD ;

Delignat, S ;

Hassan, G ;

Caligiuri, G ;

Nicoletti, A ;

Lacroix-Desmazes, S ;

Kazatchkine, MD ;

Kaveri, S .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2006, 6 (04) :528-534

[14] FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis [J].

Bergtold, Amy ;

Gavhane, Anamika ;

D'Agati, Vivette ;

Madaio, Michael ;

Clynes, Raphael .

JOURNAL OF IMMUNOLOGY, 2006, 177 (10) :7287-7295

[15] Characterization of an FcγRI-binding peptide selected by phage display [J].

Berntzen, G ;

Brekke, OH ;

Mousavi, SA ;

Andersen, JT ;

Michaelsen, TE ;

Berg, T ;

Sandlie, I ;

Lauvrak, V .

PROTEIN ENGINEERING DESIGN & SELECTION, 2006, 19 (03) :121-128

[16] Identification of a High Affinity FcγRIIA-binding Peptide That Distinguishes FcγRIIA from FcγRIIB and Exploits FcγRIIA-mediated Phagocytosis and Degradation [J].

Berntzen, Goril ;

Andersen, Jan Terje ;

Ustgard, Kristine ;

Michaelsen, Terje E. ;

Mousavi, Seyed Ali ;

Qian, Julie Dee ;

Kristiansen, Per Eugen ;

Lauvrak, Vigdis ;

Sandlie, Inger .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (02) :1126-1135

[17] Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan [J].

Bibeau, Frederic ;

Lopez-Crapez, Evelyne ;

Di Fiore, Frederic ;

Thezenas, Simon ;

Ychou, Marc ;

Blanchard, France ;

Lamy, Aude ;

Penault-Llorca, Frederique ;

Frebourg, Thierry ;

Michel, Pierre ;

Sabourin, Jean-Christophe ;

Boissiere-Michot, Florence .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) :1122-1129

[18] Identification of cyclic peptides able to mimic the functional epitope of IgG1-Fc for human FcγRI [J].

Bonetto, Stephane ;

Spadola, Loredana ;

Buchanan, Andrew G. ;

Jermutus, Lutz ;

Lund, John .

FASEB JOURNAL, 2009, 23 (02) :575-585

[19] A synthetic mimic of human Fc receptors: Defined chemical modification of cell surfaces enables efficient endocytic uptake of human immunoglobulin-G [J].

Boonyarattanakalin, Siwarutt ;

Martin, Scott E. ;

Sun, Qi ;

Peterson, Blake R. .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (35) :11463-11470

[20] R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation [J].

Braselmann, Sylvia ;

Taylor, Vanessa ;

Zhao, Haoran ;

Wang, Su ;

Sylvain, Catherine ;

Baluom, Muhammad ;

Qu, Kunbin ;

Herlaar, Ellen ;

Lau, Angela ;

Young, Chi ;

Wong, Brian R. ;

Lovell, Scott ;

Sun, Thomas ;

Park, Gary ;

Argade, Ankush ;

Jurcevic, Stipo ;

Pine, Polly ;

Singh, Rajinder ;

Grossbard, Elliott B. ;

Payan, Donald G. ;

Masuda, Esteban S. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 319 (03) :998-1008

← 1 2 3 4 5 6 7 8 9 10 →